{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:41:35Z","timestamp":1789764095532,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ekir.2024.04.024","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T10:51:05Z","timestamp":1713178265000},"page":"1995-2005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Thrombotic Microangiopathy as an Emerging Complication of Viral Vector\u2013Based Gene Therapy"],"prefix":"10.1016","volume":"9","author":[{"given":"Nora","family":"Schwotzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"El Sissy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Desguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Fr\u00e9meaux-Bacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Fakhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.04.024_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.ekir.2024.04.024_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.04.024_bib3","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.nmd.2023.09.008","article-title":"261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands","volume":"33","author":"Servais","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ekir.2024.04.024_bib4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/14712598.2022.2066471","article-title":"Onasemnogene abeparvovec for the treatment of spinal muscular atrophy","volume":"22","author":"McMillan","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ekir.2024.04.024_bib5","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: a Nonrandomized Controlled Trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ekir.2024.04.024_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11910-017-0739-9","article-title":"Huntington\u2019s disease-update on treatments","volume":"17","author":"Wyant","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.ekir.2024.04.024_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101144","article-title":"Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model","volume":"31","author":"Gushchina","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ekir.2024.04.024_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41433-021-01842-1","article-title":"Review of gene therapies for age-related macular degeneration","volume":"36","author":"Khanani","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ekir.2024.04.024_bib9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/hum.2015.025","article-title":"Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success- a personal perspective","volume":"26","author":"Hastie","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ekir.2024.04.024_bib10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.ekir.2024.04.024_bib11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1089\/hum.2017.150","article-title":"Unraveling the complex story of immune responses to AAV vectors trial after trial","volume":"28","author":"Vandamme","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ekir.2024.04.024_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101117","article-title":"Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy","volume":"31","author":"Day","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ekir.2024.04.024_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41434-022-00339-0","article-title":"Adeno-associated virus serotype 9 antibody titers in patients with SMA pre-screened for treatment with onasemnogene abeparvovec -routine care evidence","volume":"30","author":"Aharoni","year":"2023","journal-title":"Gene Ther"},{"key":"10.1016\/j.ekir.2024.04.024_bib14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.coviro.2017.06.003","article-title":"Host determinants of adeno-associated viral vector entry","volume":"24","author":"Pillay","year":"2017","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.ekir.2024.04.024_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.chom.2019.02.016","article-title":"Complement C4 prevents viral infection through capsid inactivation","volume":"25","author":"Bottermann","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ekir.2024.04.024_bib16","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/gt.2008.114","article-title":"Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors","volume":"15","author":"Appledorn","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.ekir.2024.04.024_bib17","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement is an essential component of the immune response to adeno-associated virus vectors","volume":"82","author":"Zaiss","year":"2008","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.ekir.2024.04.024_bib18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3389\/fmicb.2017.01117","article-title":"Complement evasion strategies of viruses: an overview","volume":"8","author":"Agrawal","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ekir.2024.04.024_bib19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0966-842X(00)01830-8","article-title":"Viral mechanisms of immune evasion","volume":"8","author":"Alcami","year":"2000","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.ekir.2024.04.024_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2024.04.024_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.753467","article-title":"Adeno-associated viruses (AAV) and host immunity: a race between the hare and the hedgehog","volume":"12","author":"Rapti","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.04.024_bib22","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood-2010-03-276949","article-title":"Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in\u00a0vitro and in\u00a0vivo","volume":"116","author":"Seregin","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.024_bib23","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1681\/ASN.0000000000000192","article-title":"Targeting the complement pathway in kidney transplantation","volume":"34","author":"Golshayan","year":"2023","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.04.024_bib24","first-page":"493","article-title":"Evading the immune response upon in\u00a0vivo gene therapy with viral vectors","volume":"11","author":"Sack","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.ekir.2024.04.024_bib25","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases toll-like receptor 9-dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.024_bib26","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0729","article-title":"Gene therapy for spinal muscular atrophy: safety and early outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.ekir.2024.04.024_bib27","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa2214084","article-title":"Gene therapy in patients with the Crigler-Najjar syndrome","volume":"389","author":"D\u2019Antiga","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.04.024_bib28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with Etranacogene Dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.04.024_bib29","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent beta-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.04.024_bib30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.ekir.2024.04.024_bib31","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.04.024_bib32","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving forward after two deaths in a gene therapy trial of myotubular myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ekir.2024.04.024_bib33","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1016\/j.ymthe.2023.07.020","article-title":"Liver injury in cynomolgus monkeys following intravenous and intrathecal scAAV9 gene therapy delivery","volume":"31","author":"Hudry","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.ekir.2024.04.024_bib34","doi-asserted-by":"crossref","first-page":"8798","DOI":"10.1128\/jvi.71.11.8798-8807.1997","article-title":"The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors","volume":"71","author":"Lieber","year":"1997","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.ekir.2024.04.024_bib35","first-page":"209","article-title":"Safety monitoring of gene therapy for spinal muscular atrophy with onasemnogene abeparvovec : a single center experience","volume":"8","author":"Friese","year":"2021","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.ekir.2024.04.024_bib36","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2006-06-032524","article-title":"Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance","volume":"109","author":"Othman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.024_bib37","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1016\/j.ymthe.2022.11.007","article-title":"Secondary hemophagocytic lymphohistiocytosis following Zolgensma therapy: an evolving story on the innate response to systemic gene therapy","volume":"30","author":"Byrne","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.ekir.2024.04.024_bib38","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/jcpt.13733","article-title":"Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy","volume":"47","author":"Galletta","year":"2022","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.ekir.2024.04.024_bib39","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-associated virus-induced dorsal root ganglion pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ekir.2024.04.024_bib40","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.04.024_bib41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.ekir.2024.04.024_bib42","first-page":"94","article-title":"Thrombotic microangiopathy (TMA): a potential adverse reaction post Zolgensma (onasemnogene abeparvovec-xioi) therapy for Spinal muscular atrophy (SMA)","volume":"5483","author":"Prabhu","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ekir.2024.04.024_bib43","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ekir.2024.04.024_bib44","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1212\/WNL.0000000000200676","article-title":"Child neurology: pathologically confirmed thrombotic microangiopathy caused by onasemnogene abeparvovec treatment for SMA","volume":"98","author":"Yazaki","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.ekir.2024.04.024_bib45","doi-asserted-by":"crossref","unstructured":"Mendonca R, Ortega A, Matsui C, et\u00a0al. Real world safety and exploratory efficacy of gene therapy for patients with 5q-Spinal Muscular Atrophy in a Brazilian cohort. Preprint. Posted online February 28, 2023. Research Square. https:\/\/doi.org\/10.21203\/rs.3.rs-2527927\/v1","DOI":"10.21203\/rs.3.rs-2527927\/v1"},{"key":"10.1016\/j.ekir.2024.04.024_bib46","first-page":"42","article-title":"Thrombotic microangiopathy (TMA) after gene replacemant therapy (GRT) due to spinal muscular atrophy: case summary and recommendations for treatment","volume":"234","author":"Witte","year":"2022","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.ekir.2024.04.024_bib47","first-page":"S1","article-title":"21-22 & 28-29 May 2021 Virtual, worldwide","volume":"8","year":"2021","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.ekir.2024.04.024_bib48","author":"Belluscio"},{"key":"10.1016\/j.ekir.2024.04.024_bib49","author":"Rossano"},{"key":"10.1016\/j.ekir.2024.04.024_bib50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/10430340152712665","article-title":"Toxicity of a first-generation adenoviral vector in rhesus macaques","volume":"13","author":"Lozier","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ekir.2024.04.024_bib51","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/jgm.535","article-title":"Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors","volume":"6","author":"Gruchala","year":"2004","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.ekir.2024.04.024_bib52","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1172\/JCI118367","article-title":"Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia","volume":"96","author":"Newman","year":"1995","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2024.04.024_bib53","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1128\/JVI.00082-09","article-title":"Adenovirus activates complement by distinctly different mechanisms in\u00a0vitro and in\u00a0vivo: indirect complement activation by virions in\u00a0vivo","volume":"83","author":"Tian","year":"2009","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.ekir.2024.04.024_bib54","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1073\/pnas.1814797116","article-title":"P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4\/heme-dependent manner","volume":"116","author":"Merle","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2024.04.024_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100590","article-title":"Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study","volume":"28","author":"Annane","year":"2020","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.ekir.2024.04.024_bib56","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.kint.2020.05.013","article-title":"The case of complement activation in COVID-19 multiorgan impact","volume":"98","author":"Noris","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.04.024_bib57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.04.024_bib58","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood.2021012752","article-title":"COVID-19 as a potential trigger of complement-mediated atypical HUS","volume":"138","author":"El Sissy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.024_bib59","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2023","journal-title":"J\u00a0Clin Invest"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924016474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924016474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T05:11:42Z","timestamp":1719983502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024924016474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2468024924016474"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.04.024","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic Microangiopathy as an Emerging Complication of Viral Vector\u2013Based Gene Therapy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}